[by Yu, Suin] Yuhan Corporation announced on October 6 that it is operating a dedicated booth at ‘CPHI Worldwide 2026’ (CPHI ...

[by Yu, Suin] JW Pharmaceutical announced on October 6 that it had presented Phase 3 clinical trial results for ‘EMPA-GUARD,’ ...

[by Kang, In Hyo] HLB’s novel cholangiocarcinoma drug, ‘lirafugratinib,’ has entered full regulatory review for approval in ...

[by Ji, Yong Jun] The multinational pharmaceutical company GlaxoSmithKline (GSK) is embarking on clinical development of a ...

[더바이오 유하은 기자] 미국제약협회(PhRMA)가 미국 정부의 최혜국대우(MFN) 의약품 가격 정책인 ‘GLOBE’에 제동을 걸고 나섰다. 메디케어 파트B에 도입할 예정인 이 정책이 의회의 승인 없이 의약품 가격을 통제하는 ...

[by Ji, Yong Jun] Biosolution announced on October 6 that it participated as an invited speaker at the ‘2026 4th Greater Bay ...

[by Yu, Suin] Dt&CRO has set out to strengthen its nonclinical service capabilities in the fields of ‘pharmaceuticals’ and ‘medical devices’ by expanding the s ...

[by Ji, Yong Jun] Novelty Nobility has finalized a licensing-out (L/O) agreement for ‘NN3201’ (development code), an antibody-drug conjugate (ADC) candidate ta ...

[by Ji, Yong Jun] LAMEDITECH, a company specializing in medical and beauty devices, announced on October 6 that its ‘Puraxel ...

[by Yu, Suin] Dt&CRO announced on October 2 that it is expanding the range of nonclinical analytical services available to support new drug development.DT&CRO ...

[by Kang, In Hyo] Celltrion announced that it launched Omlyclo (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in the United S ...

[by Yu, Suin] Celltrion announced on October 7 that the U.S. Food and Drug Administration (FDA) has granted an additional indication for the intravenous (IV) f ...